In the SUSTAIN clinical trial program evaluating injectable semaglutide for type 2 diabetes, the 1 mg weekly dose reduced HbA1c by approximately 1.41.6% from baseline, while the SUSTAIN FORTE trial showed that the 2 mg dose provided additional glycemic benefits for patients needing intensification
And a few operate through business models that raise questions about whether the product itself is the priority, or whether recruitment is the real revenue engine
If the prescriber cannot or will not attempt those steps, the patient can consider seeing a healthcare professional who focuses on weight management
This is particularly relevant for medications with narrow therapeutic windows, such as thyroid hormones and certain antibiotics
Theres some early data on it helping with cognitive impairment
Among the remedies are a forthcoming Medicare-Medicaid program in which drug manufacturers may offer lower GLP-1 prices and weight-loss lifestyle interventions to some enrollees